Monitoring serum calcium, phosphate, ALP and PTH levels, every 6–12 months, 3–6 months and 1–3 months in stages 2 and 3, stage 4 and stage 5, respectively, is recommended by the ‘Kidney Disease: Improving Global Outcomes (KDIGO)’ and the ‘Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines’ [74,75]. The gene discussed is PTH; the disease is kidney disorder.